1. Home
  2. BLX vs MESO Comparison

BLX vs MESO Comparison

Compare BLX & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLX
  • MESO
  • Stock Information
  • Founded
  • BLX 1977
  • MESO 2004
  • Country
  • BLX Panama
  • MESO Australia
  • Employees
  • BLX N/A
  • MESO N/A
  • Industry
  • BLX Commercial Banks
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • BLX Finance
  • MESO Health Care
  • Exchange
  • BLX Nasdaq
  • MESO Nasdaq
  • Market Cap
  • BLX 1.6B
  • MESO 1.8B
  • IPO Year
  • BLX N/A
  • MESO N/A
  • Fundamental
  • Price
  • BLX $44.83
  • MESO $16.02
  • Analyst Decision
  • BLX
  • MESO Strong Buy
  • Analyst Count
  • BLX 0
  • MESO 2
  • Target Price
  • BLX N/A
  • MESO $24.00
  • AVG Volume (30 Days)
  • BLX 140.8K
  • MESO 159.9K
  • Earning Date
  • BLX 10-28-2025
  • MESO 08-28-2025
  • Dividend Yield
  • BLX 5.61%
  • MESO N/A
  • EPS Growth
  • BLX 9.67
  • MESO N/A
  • EPS
  • BLX 6.00
  • MESO N/A
  • Revenue
  • BLX $308,426,000.00
  • MESO $17,198,000.00
  • Revenue This Year
  • BLX $18.52
  • MESO $440.77
  • Revenue Next Year
  • BLX $5.81
  • MESO $110.74
  • P/E Ratio
  • BLX $7.41
  • MESO N/A
  • Revenue Growth
  • BLX 10.24
  • MESO 191.39
  • 52 Week Low
  • BLX $31.14
  • MESO $9.61
  • 52 Week High
  • BLX $48.38
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • BLX 53.86
  • MESO 52.88
  • Support Level
  • BLX $43.39
  • MESO $14.32
  • Resistance Level
  • BLX $45.00
  • MESO $15.61
  • Average True Range (ATR)
  • BLX 0.77
  • MESO 0.57
  • MACD
  • BLX 0.12
  • MESO 0.11
  • Stochastic Oscillator
  • BLX 90.00
  • MESO 87.78

About BLX Banco Latinoamericano de Comercio Exterior S.A.

Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: